Samsung Bioepis has entered a new global agreement with Sandoz to develop and commercialise up to five next‑generation ...

Atrogi has dosed the first participants in a human study of its lead candidate ATR‑258, marking a significant step forward for the Stockholm-based biotech as it advances its next‑generation approach ...

R1 Therapeutics has launched with an oversubscribed $77.5 million Series A financing and an exclusive global licence to ...

Almirall has reported positive top-line results from its phase 3 ADorable-1 trial, which evaluated lebrikizumab in children ...

Terumo Blood and Cell Technologies has entered a new collaboration with Taiwan Bio Therapeutics to transition regulatory T‑cell manufacturing onto the automated Quantum Flex platform, marking a shift ...

Elevara Medicines has dosed the first patient in its phase 2b START-SYNERGY trial, marking a key step in the development of ELV001, an oral CDK4/6 inhibitor being studied for rheumatoid arthritis in ...

The MHRA has approved deuruxolitinib, marketed as Leqselvi, for the treatment of severe alopecia areata in adults, offering a new therapeutic option for people living with the autoimmune condition.

Aplagon has dosed the first patient in its phase 2a HEALING clinical trial evaluating APAC, a first‑in‑class treatment for thrombo‑inflammatory diseases, in people with peripheral arterial occlusive ...